University Research Lecturer
Helen Dakin is a health economist specialising in assessing the cost-effectiveness of healthcare interventions. Her research interests include methods for trial and model-based economic evaluation, with particular focus on uncertainty, interacting healthcare decisions and factorial trials.
Helen has led and collaborated on the health economic analyses of numerous randomised controlled trials, models and observational studies. Current projects include: the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component; the STAR trial, which evaluates radiotherapy alongside ranibizumab (Lucentis) in age-related macular degeneration; and the Supporting Women with adhErence to adjuvant Endocrine Therapy following breast cancer (SWEET) trial.
Helen co-leads the Patient Reported Outcomes and Health Economics module of the MSc in Clinical Trials and leads the HERC online short course Integrating Economic Evaluation into Clinical Trials.
Helen joined the Health Economics Research Centre in February 2008. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials. She previously worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry.
Research paper on factors influencing NICE decisions available here.
Health Poverty among people with Type 2 Diabetes Mellitus (T2DM) in Malaysia
Parra-Mujica F. et al, (2023), Social Science and Medicine
Trends in all-cause mortality among adults with diagnosed type 2 diabetes in West Malaysia: 2010 - 2019.
Lim L-L. et al, (2023), Diabetes Res Clin Pract, 205
Cost-effectiveness of Replacing Versus Discarding the Nail in Children with Nail Bed Injury
Dakin HA. et al, (2023), British Journal of Surgery
Effectiveness of nail bed repair in children with or without replacing the fingernail: the NINJA multicentre randomised controlled trial
JAIN A. et al, (2023), British Journal of Surgery
Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.
Dakin H. et al, (2022), Bone Jt Open, 3, 898 - 906